Murex patent infringement claims against Abbott focus on IMx, AxSYM systems.
This article was originally published in The Gray Sheet
MUREX ALLEGES PATENT INFRINGEMENT BY ABBOTT IMx AND AxSYM ANALYZERS in a complaint filed July 1 in the U.S. District Court for the Northern District of Georgia, Atlanta. Murex Diagnostics, a division of International Murex Ltd., says a filtration process used in Abbott's diagnostic analyzers infringes the Marshall Patent, No. 5,501,949, which was issued to Murex on March 26. Murex says that on March 28, it informed Abbott of the '949 patent and told Abbott that it believes the IMx Immunoassay and AxSYM System infringe certain claims of the patent.
You may also be interested in...
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.